Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients, Leukemia, vol.28, issue.5, pp.1122-1130, 2014. ,
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet, vol.394, pp.29-38, 2019. ,
Genomic complexity of multiple myeloma and its clinical implications, Nat Rev Clin Oncol, vol.14, issue.2, pp.100-113, 2017. ,
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science, vol.324, pp.930-935, 2009. ,
The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain, Science, vol.324, issue.5929, pp.929-959, 2009. ,
Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification, Nature, vol.466, issue.7310, pp.1129-1162, 2010. ,
TET1 is a tumor suppressor of hematopoietic malignancy, Nat Immunol, vol.16, issue.6, pp.653-62, 2015. ,
Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis, Genes Dev, vol.29, issue.9, pp.910-932, 2015. ,
Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA, Science, vol.333, issue.6047, pp.1303-1310, 2011. ,
Genome-wide analysis reveals TETand TDG-dependent 5-methylcytosine oxidation dynamics, Cell, vol.153, issue.3, pp.692-706, 2013. ,
Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates, PLoS ONE, vol.5, issue.12, p.15367, 2010. ,
TET enzymes, TDG and the dynamics of DNA demethylation, Nature, vol.502, issue.7472, pp.472-481, 2013. ,
Balasubramanian S. 5-Hydroxymethylcytosine is a predominantly stable DNA modification, Nat Chem, vol.6, issue.12, pp.1049-55, 2014. ,
5-Formylcytosine can be a stable DNA modification in mammals, Nat Chem Biol, vol.11, issue.8, pp.555-562, 2015. ,
5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells, Genome Biol, vol.12, issue.6, p.54, 2011. ,
Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers, Nucleic Acids Res, vol.40, issue.17, pp.8255-65, 2012. ,
Cytosine modifications modulate the chromatin architecture of transcriptional enhancers, Genome Res, vol.27, issue.6, pp.947-58, 2017. ,
5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers, Cell Res, vol.27, issue.10, pp.1243-57, 2017. ,
5-Hydroxymethylcytosine signatures in cellfree DNA provide information about tumor types and stages, Cell Res, vol.27, issue.10, pp.1231-1273, 2017. ,
The role of 5-hydroxymethylcytosine in human cancer, Cell Tissue Res, vol.356, issue.3, pp.631-672, 2014. ,
Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer, Cell Res, vol.26, issue.1, pp.103-121, 2016. ,
Christensen BC. 5-Hydroxymethylcytosine localizes to enhancer elements and is associated with survival in glioblastoma patients, Nat Commun, vol.7, issue.1, pp.1-11, 2016. ,
5-Hydroxymethylcytosine and teneleven translocation dioxygenases in head and neck carcinoma, J Cancer, vol.10, issue.21, pp.5306-5320, 2019. ,
Portraits of TET-mediated DNA hydroxymethylation in cancer, Curr Opin Genet Dev, vol.36, pp.16-26, 2016. ,
Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence?, Genomics, vol.104, issue.5, pp.352-359, 2014. ,
Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers, Genome Res, vol.25, issue.4, pp.478-87, 2015. ,
DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors, Cancer Res, vol.70, issue.17, pp.6934-6978, 2010. ,
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma, Blood, vol.117, issue.2, pp.553-62, 2011. ,
Myeloma is characterized by stagespecific alterations in DNA methylation that occur early during myelomagenesis, J Immunol, vol.190, issue.6, pp.2966-75, 2013. ,
The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation, Haematologica, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02165596
, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, The International Myeloma Working Group, vol.121, pp.749-57, 2003.
The genetic architecture of multiple myeloma, Nat Rev Cancer, vol.12, issue.5, pp.335-383, 2012. ,
Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma, Blood, vol.131, pp.2138-50, 2018. ,
International staging system for multiple myeloma, J Clin Oncol, vol.23, issue.15, pp.3412-3432, 2005. ,
Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine, Nat Biotechnol, vol.29, issue.1, pp.68-72, 2011. ,
Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation, Nature, vol.473, issue.7347, pp.398-402, 2011. ,
Master transcription factors and Mediator establish super-enhancers at key cell identity genes, Cell, vol.153, issue.2, pp.307-326, 2013. ,
A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping, Cell, vol.159, issue.7, pp.1665-80, 2014. ,
Models of human core transcriptional regulatory circuitries, Genome Res, vol.26, issue.3, pp.385-96, 2016. ,
Minor clone provides a reservoir for relapse in multiple myeloma, Leukemia, vol.27, issue.2, pp.473-81, 2013. ,
A genome-wide association study identifies a novel locus for bortezomib-induced peripheral neuropathy in European patients with multiple myeloma, Clin Cancer Res, vol.22, issue.17, pp.4350-4355, 2016. ,
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer, Nature, vol.481, issue.7381, pp.389-93, 2012. ,
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells, Science, vol.343, issue.6168, pp.301-306, 2014. ,
convenient online submission ? thorough peer review by experienced researchers in your field ? rapid publication on acceptance ? support for research data, including large and complex data types ? gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year ? At BMC, research is always in progress. Learn more biomedcentral.com/submissions Ready to submit your research Ready to submit your research ? Choose BMC, Choose BMC and benefit from ,
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins, Science, vol.343, issue.6168, pp.305-314, 2014. ,
MK2 is a therapeutic target for high-risk multiple myeloma. Haematologica, 2018. ,
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2, Nature, vol.468, issue.7325, pp.839-882, 2010. ,
Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: normalization of plasma vitamin C induces epigenetic changes, Clin Epigenetics, vol.11, issue.1, p.143, 2019. ,
Isotope-dilution mass spectrometry for exact quantification of noncanonical DNA nucleosides, Nat Protoc, vol.14, issue.1, pp.283-312, 2019. ,
, Publisher's Note
, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations